Related Experiment Video

Updated: Aug 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Can antiarrhythmic drugs save lives in patients with congestive heart failure?

Bente Brendorp1, Ole Dyg Pedersen, Hanne Elming

  • 1Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark. bb@heart.dk

Expert Review of Cardiovascular Therapy
|March 20, 2004
PubMed

Insights

Antiarrhythmic drugs offer limited benefits for congestive heart failure (CHF) patients, with beta-blockers being the only exception for mortality reduction. Current strategies for atrial fibrillation in CHF require re-evaluation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Arrhythmic death is a significant cause of mortality in congestive heart failure (CHF) patients.
  • Prophylactic antiarrhythmic drug treatments have largely failed to demonstrate significant mortality benefits in CHF.
  • Atrial fibrillation is a common comorbidity in CHF, complicating treatment strategies.

Purpose of the Study:

  • To review large clinical trials on antiarrhythmic drug treatment in CHF patients.
  • To analyze treatment efficacy in CHF patients with and without atrial fibrillation.
  • To discuss future therapeutic possibilities for managing arrhythmias in CHF.

Main Methods:

  • Systematic review of major clinical trials concerning antiarrhythmic drug therapy in CHF.
  • Analysis of subgroup data focusing on patients with and without atrial fibrillation.
  • Evaluation of mortality reduction and antiarrhythmic effects of various drug classes.

Main Results:

  • Most antiarrhythmic drugs have shown minimal impact on mortality in CHF.
  • Beta-blockers are the only class demonstrating a clear mortality-reducing effect.
  • The benefits of gamma-blockers may stem from non-antiarrhythmic mechanisms.

Conclusions:

  • Current antiarrhythmic drug strategies for CHF require reassessment, particularly regarding atrial fibrillation.
  • Beta-blockers remain a cornerstone therapy for improving survival in CHF.
  • Future research should explore novel therapeutic approaches beyond traditional antiarrhythmic effects.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...